RenovoRx Inc

RNXT

Company Profile

  • Business description

    RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.

  • Contact

    2570 West El Camino Real
    Suite 320
    Mountain ViewCA94040
    USA

    T: +1 650 284-4433

    https://www.renovorx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    10

Stocks News & Analysis

stocks

Our view of BHP after June quarter results

Record copper volumes are reported.
stocks

James Hardie transfers of share listing to New York Stock Exchange

The change is a result of the controversial Azek acquisition.
stocks

The 10 best US dividend stocks

These are the top dividend-paying stocks to buy in 2025.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,926.2080.60-0.89%
CAC 407,805.8916.78-0.21%
DAX 4024,289.320.19-0.00%
Dow JONES (US)44,342.19142.30-0.32%
FTSE 1008,995.173.050.03%
HKSE24,994.14168.480.68%
NASDAQ20,895.6510.010.05%
Nikkei 22539,819.1182.08-0.21%
NZX 50 Index12,961.5181.110.63%
S&P 5006,296.790.57-0.01%
S&P/ASX 2008,668.2089.00-1.02%
SSE Composite Index3,559.7925.310.72%

Market Movers